New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness
CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gummies.
+PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen®+ PEA, the CBD-like compound shown by clinical studies to be an alternative to ibuprofen. This highly optimized trio promotes a healthy inflammatory response and provides a safe alternative in helping to manage occasional soreness.
“We believe that +PlusCBD Relief Softgels contain the safest, purest and most effective source of CBD/CBDA available on the market today,” said Joseph Dowling, Chief Executive Officer of CV Science. “Our work at CV Sciences centers around the potential for CBD to transform our understanding of health, wellness and pain relief. The +PlusCBD Relief Softgels represent another step in our mission to offer innovative and safe alternatives to improve health, leveraging CBD/CBDA and PEA. Our product development team creates best-in-class, innovative products that suit individual preferences, address need states and help consumers benefit from CBD in the way that works best for them. Our Relief product is now available directly from our website www.pluscbdoil.com and soon from select retailers.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 8,400 retail locations throughout the U.S. and it is one of the top-selling brands of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Forward Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.
Contact Information
Investor Contact:
ICR
Reed Anderson
646-277-1260
[email protected]
Media Contact:
ICR
Cory Ziskind
646-277-1232
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/57df619a-f57d-409c-8385-25478808872f
Related Quotes
Inovio Pharmaceuticals(NASDAQ: INO) was an early star in the coronavirus vaccine race. Inovio during its earnings report last week said it was halting enrollment of its vaccine trial to update the endpoint. This will once again lengthen the development timeline — and delay potential commercialization.
Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022. Earlier, the data were anticipated in Q1 of 2022. The study enrolled more than 400 patients across 30 sites in Europe, Israel, and Canada. Piclidenoson is an A3 adenosine receptor agonist (A3AR) small molecule that inhibits interleukin-17 and interleukin-23, both pivotal f
The stock slid, but then regained ground. The company said it would provide more details of the study at an “upcoming medical conference.”
Scientists have pinpointed 16 new genetic variants in people who developed severe COVID-19 in a large study published on Monday that could help researchers develop treatments for very sick patients. The results suggest that people with severe COVID have genes that predispose them to one of two problems: failure to limit the ability of the virus to make copies of itself, or excessive inflammation and blood clotting. "It is potentially possible in future that we will be able to make predictions about patients based on their genome at the point of presenting (for) critical care," said Kenneth Baillie, consultant in critical care medicine at the University of Edinburgh and one of the study authors, told reporters.
The COVID antibody drug Evusheld, which the FDA authorized in December to help protect immunocompromised people before they're exposed to the virus, is often going unused because of confusion among health care providers, the New York Times reports.Why it matters: The drug, made by AstraZeneca, is seen as a critical tool for some of the most vulnerable Americans or those who can't be vaccinated — but only if they can access it.Get market news worthy of your time with Axios Markets. Subscribe for
Hoosier Health column
(Reuters) -Board members at Russian companies, including the British chairmen of gold and silver producer Polymetal and metals and hydropower group EN+, have quit in response to the conflict in Ukraine. Polymetal said on Monday Chairman Ian Cockerill and five other non-executive independent directors — Ollie Oliveira, Tracey Kerr, Italia Boninelli, Victor Flores and Andrea Abt — had left the London-listed company's board. Polymetal gave no further details of the departures that coincide with concerns over the impact of Russia's invasion of Ukraine and subsequent Western sanctions on Russia.
Here's what to watch in the markets on Monday, March 7, 2022.
Southeast Asian stocks are becoming a haven for international investors fleeing a worsening outlook for global equities who are hoping for sustained strength in the commodity-heavy economies of the region. Driving the renewed interest is a surge in commodity prices that spells good news, particularly for key producers Indonesia and Malaysia, coupled with the sparse economic links between Southeast Asia and the warring nations of Russia and Ukraine. Supply disruptions caused by the conflict and subsequent Western sanctions have sent commodities prices soaring, with Brent crude, coal, palm oil and nickel hitting multi-year highs.
(Bloomberg) — The head of the biggest U.S. oil lobby groups said the Biden administration is “misusing facts” when it claims the industry has more than 9,000 federal drilling permits on which it can drill to boost supply and ease soaring energy prices. Most Read from BloombergUkraine Update: Global Stocks Plunge; Russia Threatens Gas FlowChina Warns U.S. Over Forming Pacific NATO, Backing TaiwanBiden to Sign Crypto Order as Firms Face Sanctions PressureCovid Can Shrink the Brain as Much as a De
Ryan Cohen’s 9.8% stake in the housewares retailer is reminiscent of his move to amass a position in GameStop and lay the groundwork to take over the company’s board.
Hundreds of Chinese companies are listed on U.S. markets. But which are the best Chinese stocks to buy or watch right now? JD.com , NetEase, Li Auto, Xpeng and BYD Co.. China is the world's most-populous nation and the second-largest economy with a booming urban middle class and amazing entrepreneurial activity.
The Indian rupee sank to its lowest ever against the US dollar today (March 7) as the war between Russia and Ukraine drove up crude prices to multi-year highs globally. The surge in crude oil prices is now likely to increase the country’s oil import bill, more so because India imports nearly 80% of its fuel needs. Since India is one of the largest importers of crude oil, it is more vulnerable.
Aecom said Friday it is "immediately exiting" its business operations in Russia, given what the consulting firm's Chief Executive Troy Rudd called Russia's "unlawful invasion" of Ukraine. The company said the financial contribution to its businesses related to Russia is not material, and therefore reiterated its fiscal 2022 financial guidance provided a month ago for adjusted earnings per share of between $3.30 and $3.50, which surrounds the current FactSet consensus of $3.44. The company said i
Embraer SA (NYSE: ERJ) enters the air freight market with the E190F and E195F Passenger to Freight Conversions (P2F) launch. These E-Jets freighters are designed to meet the changing demands of e-commerce and modern trade that require fast deliveries and decentralized operations. The full freighter conversion is available for all pre-owned E190 and E195 aircraft, with service expected in early 2024. Embraer sees a market for ~700 aircraft over 20 years. The company plans to perform freighter con
Offset purchased options with a sold options
Alphabet Inc. plans to acquire Mandiant Inc. for roughly $5.4 billion in a deal that highlights growing interest in cybersecurity.
Technically, we're not seeing claws and sharp teeth. But in the practice, this is a hard time to trade.
Ben McMillan of IDC Digital Assets joins “First Mover” to address the current state of the crypto markets as Russia’s invasion of Ukraine shows no signs of slowing down. McMillan addresses the soaring price of oil as Western countries are mulling a Russia oil ban. Plus, comparing bitcoin to gold as a storage of value in time of crisis.
U.S. stock indexes tumble Monday, leaving the blue-chip index in correction territory and the Nasdaq Composite in a bear market, as the U.S. considers a ban on Russia oil imports.
